A Precision FGFR Inhibitor for Cholangiocarcinoma

　　Futibatinib is an orally administered small molecule targeted therapy designed to selectively inhibit fibroblast growth factor receptors(FGFR1-4).By precisely blocking aberrant FGFR kinase activity,it disrupts cancer cell proliferation and survival pathways,offering a transformative approach for specific cholangiocarcinoma patients.

　　Key Features：

　　1.Targeted Mechanism：

　　Acts as a potent and selective FGFR1-4 inhibitor,competitively binding to the ATP-binding site of FGFR kinases.This blockade suppresses receptor phosphorylation and downstream signaling(RAS/MAPK,PI3K/AKT),effectively halting tumor growth,metastasis,and angiogenesis.

　　2.Indications&Eligibility：

　　Approved for adult patients with locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements who have progressed on≥1 prior systemic therapy.Requires confirmatory genetic testing for actionable FGFR alterations.

　　3.Global Availability&Pricing Insights：

　　○Not currently approved in Mainland China;access limited to regions with market authorization.

　　○International options include:

　　■Japan(brand-name version):4mg×35 tablets priced at approximately¥30,000(subject to regional pricing).

　　■Laos(generic version):Equivalent规格priced at approximately¥2,400.

　　4.Clinical Efficacy：

　　In pivotal trials,Futibatinib demonstrated robust antitumor activity in FGFR2 fusion-positive patients:

　　○Objective Response Rate(ORR):40%(tumor shrinkage/disappearance).

　　○Median Progression-Free Survival(PFS):8 months,improving outcomes for heavily pretreated populations.

　　Treatment Considerations：

　　●Mandatory genetic testing to confirm FGFR eligibility.

　　●Regular monitoring for safety,including laboratory assessments and adverse event management.

　　●Avoid concomitant use of strong CYP3A inhibitors/inducers to prevent drug interactions.